Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

EJHaem Pub Date : 2025-05-06 DOI:10.1002/jha2.70049

Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza-Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Ravi Bhatia, Omer Jamy

{"title":"Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia","authors":"Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza-Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Ravi Bhatia, Omer Jamy","doi":"10.1002/jha2.70049","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Real-world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We evaluated outcomes of patients with newly-diagnosed AML treated with HMA + VEN50 with either posaconazole (<i>n</i> = 23) or voriconazole (<i>n</i> = 95).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.</p>\n </section>\n \n <section>\n \n <h3> Clinical trial registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70049","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Real-world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited.

Methods

We evaluated outcomes of patients with newly-diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95).

Results

We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.

Conclusion

HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.

Clinical trial registration

The authors have confirmed clinical trial registration is not needed for this submission.

查看原文本刊更多论文

Venetoclax 50mg，低甲基化药物，Voriconazole或泊沙康唑治疗急性髓系白血病

低甲基化剂(HMA) + venetoclax 50mg （VEN50）与伏立康唑和泊沙康唑联合治疗急性髓性白血病（AML）的实际证据有限。方法评价HMA + VEN50治疗的新诊断AML患者泊沙康唑（n = 23）或伏立康唑（n = 95）的预后。结果我们报告，HMA + VEN50治疗与任何一种唑引起的反应率与VIALE-A试验中描述的相似。将强CYP3A4抑制剂的VEN剂量减少到50mg并不影响联合治疗的疗效。结论HMA + VEN50联合泊沙康唑或伏立康唑与先前报道的高剂量VEN疗效相当。临床试验注册作者已确认该提交不需要临床试验注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量